title: [Clinical characterization of CA19-9 in patients with interstitial pneumonia showing pathological nonspecific interstitial pneumonia pattern].
abstract: OBJECTIVE
  To assess the clinical significance of CA19-9 in patients with interstitial pneumonia showing pathological nonspecific interstitial pneumonia (NSIP) pattern (IP/NSIP groups), we measured the levels of serum (n = 14) and bronchoalveolar lavage fluid (BALF, n = 10) CA19-9 in IP/NSIP groups.
  
  
  RESULTS
  The serum levels of CA19-9 did not correlate with the serum levels of LDH, of KL-6, or of SP-D or with the intensity of chest Ga-67 scintigraphy. There were no significant differences between the serum CA19-9 levels before therapy and those after therapy in improving patients. The levels of CA19-9 in fibrotic NSIP groups (serum:n = 7, 138.3 + /- 79.6 U/ml BALF: n = 5, 845.8 + /- 334.2 U/ml) were significantly higher than those in cellular NSIP groups (serum: n = 7, 12.8 +/-2.1 U/ml, BALF: n = 5, 40.8 +/- 16.2 U/ml). Immunohistochemical stains of CA19-9 showed the strong positivity in the bronchiolar epitheliums located in severe fibrotic lesions and the mucus within the lumens of microscopic honeycomb. The serum levels of CA19-9 were increased in both worsening patients.
  
  
  CONCLUSIONS
  We speculated that the serum levels of CA19-9 may reflect the progression of lung fibrosis but not the disease activity in IP-NSIP groups.
authors.affiliation: Division of Respirology& Allergology, Department of Internal Medicine, School of Medicine, Fujita Health University.
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Totani
authors.forename: Yuji
authors.initials: Y
authors.lastname: Saito
authors.forename: Hiromi
authors.initials: H
authors.lastname: Miyachi
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yoneda
authors.forename: Hideyasu
authors.initials: H
authors.lastname: Shimizu
authors.forename: Tami
authors.initials: T
authors.lastname: Hoshino
authors.forename: Masamichi
authors.initials: M
authors.lastname: Hayashi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Uchiyama
authors.forename: Sumito
authors.initials: S
authors.lastname: Isogai
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Matsui
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Masaya
authors.initials: M
authors.lastname: Umemoto
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Sasaki
authors.forename: Mitsushi
authors.initials: M
authors.lastname: Okazawa
authors.forename: Hiroki
authors.initials: H
authors.lastname: Sakakibara
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D001980:Bronchi / Q000378:metabolism; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D018395:CA-19-9 Antigen / Q000032:analysis* / Q000097:blood; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017563:Lung Diseases, Interstitial / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000175:diagnosis*; D020545:Respiratory Mucosa / Q000378:metabolism; D012189:Retrospective Studies
chemical_list: D015415:Biomarkers; D018395:CA-19-9 Antigen